Stay Up to Date
Breaking News,
Updates, & More
Click Here to

Eribulin Associated With Less Neuropathy Than Ixabepilone in a Prospective, Randomized Study

TOP - February 2012, Vol 5, No 1 published on February 28, 2012 in Breast Cancer

In a randomized phase 2 study of metastatic breast cancer patients, peripheral neuropathy (PN) was less likely to occur in patients receiving eribulin mesylate than with ixabepilone.

“Peripheral neuropathy is a big problem in the treatment of breast cancer. Across the spectrum, patients have it, and we don’t know how to treat it,” said Linda T. Vahdat, MD, of Weill Cornell Medical College in New York, who presented the study at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium (Poster P5-19-02).

“If we want to be able to identify patients at risk for peripheral neuropathy and develop strategies to manage it we need to characterize it better. This trial was conceived and started after the close of the EMBRACE trial. It gave us the opportunity to get a better handle on how eribulin performed from the perspective of side effects. The endpoint was the incidence of neuropathy.”

EMBRACE demonstrated that eribulin treatment significantly im­proved median overall survival by 2.5 months compared with standard treatments in heavily pretreated metastatic breast cancer patients. The overall incidence of PN in eribulin-treated patients was 35% and was mostly mild; grade 3 was seen in 8% and grade 4 in <1%.

The current study prospectively evaluated PN in 101 heavily pretreated metastatic breast cancer patients who were randomized to eribulin or ixabepilone as single agents on an every-3-week schedule; the mean number of treatment cycles was 6.2 in the eribulin group and 4.8 in the ixabepilone group. Almost one-third of patients in each arm had received at least 6 prior agents.

“We found the incidence of neuropathy was about 13% lower with eribulin,” Vahdat reported. PN of any grade occurred in 31% of the eribulin group and 44% of the ixabepilone group. Grade 3/4 PN occurred in 10% versus 20%, respectively. The difference numerically favored eribulin, though it was not statistically significant, she added. 

“Most importantly,” she said, “the median time to the onset of treatment-emergent neuropathy was longer in the eribulin group: 36 weeks versus only about 12 weeks with ixabepilone. By cycle 4, only 24% of patients receiving eribulin had developed neuropathy, compared to 44% receiving ixabepilone.”

Figure. Waterfall graphs of percent change in summed longest diameter of target lesions from baseline to nadir in patients receiving a) eribulin or b) ixabepilone according to RECIST (ITT population)Courtesy of Prash Krishna, MBBS, MRCS.

In addition, safety end points, including objective response rate and progression-free survival, based on Response Evaluation Criteria in Solid Tumors, showed greater reduction in the longest diameter of target lesions (ie, reducing tumor size) with eribulin (~80%) compared with ixabepilone (~70%) from baseline to nadir, as well as faster rate of change with eribulin, as shown in the Figure.

Vahdat acknowledged that if ixabepilone were given weekly, as it often is, the incidence of PN would be lower. The study followed the FDA-approved dosing schedule.

Related Items
FDA Updates Mammography Regulations in MQSA Final Rule
TOP - May 2023 Vol 16, No 3 published on May 15, 2023 in Breast Cancer, Healthcare Policy
Pausing Endocrine Therapy to Become Pregnant Appears Safe for Women with Breast Cancer
Patricia Stewart
TOP - March 2023 Vol 16, No 2 published on March 14, 2023 in Breast Cancer, SABCS
Factors Associated with Greater Risk for Abemaciclib Discontinuation in Patients with Early-Stage Breast Cancer
William King
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in Breast Cancer
Radiation Therapy May Be Omitted for Some Older Women with Luminal A Breast Cancer
Patricia Stewart
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in Breast Cancer
Trastuzumab Deruxtecan Represents New Standard of Care for Patients with HER2-Low Metastatic Breast Cancer
William King
TOP - September 2022 Vol 15, No 5 published on September 15, 2022 in Breast Cancer
Pembrolizumab plus Chemotherapy Prolongs Survival in Patients with Triple-Negative Breast Cancer and PD-L1 Combined Positive Score ≥10
Patricia Stewart
TOP - March 2022 Vol 15, No 2 published on March 16, 2022 in SABCS, Breast Cancer
Trastuzumab Deruxtecan Beats Trastuzumab Emtansine as Second-Line Therapy for HER2-Positive Metastatic Breast Cancer
TOP - March 2022 Vol 15, No 2 published on March 16, 2022 in SABCS, Breast Cancer
Olaparib Extends Disease-Free Survival in Patients with Early-Stage Breast Cancer and BRCA Mutation
William King
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in Breast Cancer
Tucatinib plus Trastuzumab and Capecitabine Triplet Maintains Survival Benefit in HER2-Positive Metastatic Breast Cancer: Updated Results from HER2CLIMB Trial
Charlie Dawson
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Breast Cancer
Cryoablation Appears Safe and Effective in Low-Risk, Early-Stage Breast Cancer
William Ackerman
TOP - July 2021 Vol 14, No 4 published on July 20, 2021 in Breast Cancer
Last modified: July 22, 2021